Establishment Labs Holdings (ESTA) Current Deferred Revenue (2023 - 2024)
Establishment Labs Holdings' (ESTA) quarterly Current Deferred Revenue came in at $1.7 million in Q3 2024, little changed quarter-over-quarter from $1.7 million in Q2 2024.
Establishment Labs Holdings (ESTA) Current Deferred Revenue (2023 - 2024) Analysis & Trends
Establishment Labs Holdings' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.7 million for Q3 2024.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $1.7 million in Q3 2024; TTM through Sep 2024 was $1.7 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.8 million, changed N/A from the prior year.
- Current Deferred Revenue was little changed at $1.7 million in Q3 2024 per ESTA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.8 million in Q4 2023 and bottomed at $1.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Establishment Labs Holdings | 2.73 Bn | 2.66 Bn | 42.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.84 Mn |